DOTA-NI-FAPI-04 

DOTA-NI-FAPI-04 is a FAP inhibitor (IC₅₀ = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact^[1].

1154.18

C₅₁H₆₉F₂N₁₅O₁₄

3078291-78-5

O=C(CN1CCN(CCN(CCN(CC1)CC(O)=O)CC(O)=O)CC(N[C@@H](CCC(NCCCN2C=CN=C2[N+]([O-])=O)=O)C(N3CCN(CCCOC4=CC=C(C5=C4)N=CC=C5C(NCC(N6[C@@H](CC(F)(C6)F)C#N)=O)=O)CC3)=O)=O)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Luo Y, et al. Development of [68Ga]Ga/[177Lu]Lu-DOTA-NI-FAPI-04 Containing a Nitroimidazole Moiety as New FAPI Radiotracers with Improved Tumor Uptake and Retention. J Med Chem. 2025 Jan 9;68(1):348-360.  [Content Brief]